The anticipated result will be that silencing LIS1 influences the fate of CSC and therefore the consequent change in stem cell markers expression such as a decrease of the CD133+ CSC fraction (for other solid cancers we expect a decrease in other CSC markers such as CD44, CD49f, A2B5) in the silenced/knocked-out LIS1 cancer cells, as well as lower proliferation, adhesion and migration rates compared with controls. The gene discussed is ITGA6; the disease is cancer.